Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis (EQlips)
End Stage Renal Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prospective, Observational and Multi-center Study of a Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis|
- Change in Quality of Life [ Time Frame: 1yr ]change in quality of life and patient satisfaction scores from start to dialysis to 1yr between APD group and CAPD group.
Biospecimen Retention: Samples Without DNA
|Study Start Date:||October 2010|
|Study Completion Date:||September 2015|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
which can be 3 to 5 exchanges daily, and up to 20 liters daily( including up to two daytime exchanges)
which can be 1 to 4 exchanges daily and up to 16 liters daily(including up to two daytime exchanges)
Automated peritoneal dialysis (APD) was first described in 1981, 5 years after the introduction of continuous ambulatory peritoneal dialysis (CAPD). It is increasingly used increasingly used in comparison with CAPD from 20% in 1995 to more than 33% of PD patients in North America in 1998, and in 2000, 54% of PD patients in the United States performed some form of APD.
APD has been several advantages over CAPD such as reduced incidence of peritonitis, mechanical complications and greater psychosocial acceptability. Many studies demonstrated a benefit for APD. In one Mexican retrospective study, APD has a better technical survival than CAPD with improvement of 1st peritonitis episode and French registry data showed the better peritonitis-free probability and autonomy in APD compared to CAPD. One study found that peritonitis rates and hospitalization were significantly less in patients on APD when results were expressed as episode/patient-year. Also a small randomized clinical trial comparing APD and CAPD showed that APD can help to keep selected patients vocationally or socially active.
Although APD has been expected to improve better condition of peritoneal dialysis patients, convincing evidence of major advantages is lacking and a benefit for APD is not demonstrated.
In three of randomized clinical trials, APD, APD did not differ from CAPD with respect to mortality (RR 1.49, 95% CI 0.51 to 4.37), risk of peritonitis(RR 0.75, 95% CI 0.50 to 1.11), switching from original PD modality to a different dialysis modality(RR 0.50, 95% CI 0.25 to 1.02), hernias(RR 1.26, 95% CI 0.32 to 5.01), PD fluid leaks(RR 1.06, 95% CI 0.11 to 9.83), PD catheter removal ( RR 0.64, 95% CI 0.27 to 1.48) or hospital admissions (RR0.96, 95% CI 0.43 to 2.17). In addition APD has potential disadvantages compared with CAPD like a possible faster in residual renal function, less sodium removal and more peritoneal protein loss and more expensive than CAPD. All of three large cohorts, NECOSAD, USRDS and ANZDATA showed that the risk of technical failure was not different between APD and CAPD but similar.
Because results on comparison between APD and CAPD is vague, prospective, observational and multi-center study in incident patients are required to gain more insight into survival on APD compared with CAPD in the course of peritoneal dialysis.
Quality of Life is an important outcome parameter when advising patients on renal replace treatment modality section. The introduction of a machine to assist the patient with PD exchanges can potentially improve quality of life in different ways. De Wit et al. analyzed health-related quality of life (HRQOL) in 37 APD and 59 CAPD patients from 16 different Dutch dialysis centers. In a multivariate analysis, the mental health was found to be better in APD as compared to CAPD patients. In addition, there were indications that APD patient tended to be less depressed and anxious than CAPD patients. In a prospective randomized trial, Bro et al. found no difference between CAPD and APD patients in quality of life measures. However APD patient tended to have more time for work, family, and social activities as compared to CAPD patients.
From these limited data, it can possibly be concluded that quality of life is very important to evaluate the lifestyle of the patient and to adapt the PD regimen.
Therefore, quality of life (QoL) assessment is expected to evidence to support the hypothesis that APD is superior to CAPD.
And the incidences of clinical events treatment modality change, peritonitis episode, exit site/tunnel infection, hospitalization, death, cancer development) are also reviewed to support that hypothesis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01209273
|Korea, Republic of|
|Inje University Haeundae Paik Hospital|
|Busan, Korea, Republic of, 614-735|
|Samsung Changwon Hospital|
|Changwon, Korea, Republic of, 630-520|
|Chungbuk National University Hospital|
|Cheongju, Korea, Republic of, 361-790|
|Kyungpook National University Hospital|
|Daegu, Korea, Republic of, 700-721|
|Daegu Fatima Hospital|
|Daegu, Korea, Republic of, 701-600|
|Eulji University Hospital|
|Daejeon, Korea, Republic of, 302-799|
|Chosun University Hospital|
|Gwangju, Korea, Republic of, 501-717|
|Jeju National University Hospital|
|Jeju, Korea, Republic of|
|Korea University Anam Hospital|
|Seoul, Korea, Republic of, 136-705|
|Eulji General Hospital|
|Seoul, Korea, Republic of, 139-711|
|St. Carolo Hospital|
|Suncheon, Korea, Republic of, 501-757|
|Principal Investigator:||Yong-Lim Kim, M.D., Ph.D.||Division of Nephrology, Department of Internal Medicine, Kyungpook National University School of Medicine|